NCT07533747

Brief Summary

Some people experience chest pain and shortness of breath, but when they have tests, no blockages are found in their main heart arteries. The most common cause of symptoms is related to abnormalities in the small blood vessels, also known as 'small vessel angina' or Coronary Microvascular Dysfunction (CMD). Currently, the diagnosis of CMD requires additional measurements of blood flow in the heart vessel during a minimally invasive procedure known as a coronary angiogram. CMD affects many people and can lead to repeated hospital visits and a lower quality of life, and diagnosing the condition leads to better patient outcomes. However, there are still no widely available, proven treatments for this condition and therefore several patients remain symptomatic. This study aims to find better ways to treat CMD, especially by understanding how the heart uses energy and how this might relate to symptoms.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P25-P50 for phase_3

Timeline
58mo left

Started May 2026

Longer than P75 for phase_3

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress5%
May 2026May 2031

First Submitted

Initial submission to the registry

April 10, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 16, 2026

Completed
15 days until next milestone

Study Start

First participant enrolled

May 1, 2026

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2031

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2031

Last Updated

April 16, 2026

Status Verified

April 1, 2026

Enrollment Period

5 years

First QC Date

April 10, 2026

Last Update Submit

April 10, 2026

Conditions

Coronary Microvascular Dysfunction (CMD)

Outcome Measures

Primary Outcomes (1)

  • Myocardial Perfusion Reserve

    Perfusion Cardiac Magnetic Resonance Imaging

    8 weeks

Study Arms (1)

Empagliflozin Therapy Arm

EXPERIMENTAL

Empagliflozin 10mg OD

Drug: Empagliflozin 10mg OD

Interventions

Empagliflozin 10mg ODDRUG

Drug

Empagliflozin Therapy Arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Angina with non-obstructive coronary arteries

You may not qualify if:

  • Significant epicardial coronary stenoses
  • Inability to carry out bike exercise
  • Contra-indication to adenosine administration
  • Insulin usage with frequent hypoglycaemic episodes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

empagliflozin

Central Study Contacts

Haseeb Rahman, MA BMBCh MRCP PhD

CONTACT

United Kingdomhaseeb.rahman@kcl.ac.uk

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 10, 2026

First Posted

April 16, 2026

Study Start

May 1, 2026

Primary Completion (Estimated)

May 1, 2031

Study Completion (Estimated)

May 1, 2031

Last Updated

April 16, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share